ArticleFrontiers in oncology2026
Case Report: imaging features of anaplastic lymphoma kinase-rearranged renal cell carcinoma with a novel
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic lymphoma kinase (ALK)-rearranged renal cell carcinoma (ALK-RCC) is an extremely rare subtype of RCC, accounting for less than 1% of all cases. Its computed tomography (CT) features remain poorly characterized, hindering preoperative diagnosis. We report the case of a 34-year-old female who presented with painless gross hematuria. Abdominal ultrasound revealed a well-circumscribed, hyperechoic heterogeneous mass in the upper pole of the right kidney. Contrast-enhanced CT demonstrated a solitary, medullary-based hypodense mass with multiple punctate and patchy calcifications and mild heterogeneous enhancement. The patient underwent laparoscopic nephron-sparing surgery with complete resection. Histopathology showed papillary architecture with ISUP/WHO grade 2 atypical cells. Immunohistochemistry was diffusely positive for ALK (clone D5F3). Fluorescence in situ hybridization confirmed ALK rearrangement, and next-generation sequencing identified a novel DCTN1::ALK fusion-the first report of such a fusion in ALK-RCC. Follow-up showed no evidence of recurrence. This case highlights distinctive CT features of ALK-RCC that may raise suspicion in young patients and guide molecular testing. The identification of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.